SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Despite SBRT to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.

Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim ...

SBRT is noninferior to traditional radiation for low- to intermediate-risk localized prostate cancer, offering a viable treatment alternative. The PACE-B study showed a 95.8% five-year rate of no ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

The use of magnetic resonance–guided daily adaptive stereotactic body radiotherapy (SBRT) for patients with prostate cancer reduces the risk of acute urinary side effects of grade 2 or higher by 44% ...

Regarding disease-free survival, 88.6% of patients in the SBRT group were free from disease progression after three years, compared to 92.1% receiving longer courses of radiation. The difference was ...

As part of the “Speaking Out” series, a radiation oncologist discusses the benefits of MRI-guided stereotactic body radiation therapy. Dr. Matthew Solhjem, a radiation oncologist with Providence ...

Crossing Borders: Improving Mental Health Outcomes in Asian American Immigrants With Cancer When considering how to improve the efficacy of RT when treating cancer, radiobiologic principles have ...

Stereotactic body radiation therapy, which uses extremely precise, intense doses of radiation, proved to be effective at controlling lung cancer that had spread to a small number of sites. Systemic ...